REGENXBIO Inc.RGNXEarnings & Financial Report
REGENXBIO Inc. is a clinical-stage biotechnology firm focused on gene therapy for rare severe genetic diseases. It licenses its proprietary AAV vector technology to global biopharma partners, and advances its own pipeline targeting ophthalmology, metabolic and neurodegenerative disorders.
RGNX Q4 FY2025 Key Financial Metrics
Revenue
$30.3M
Gross Profit
N/A
Operating Profit
$-57.6M
Net Profit
$-67.1M
Gross Margin
N/A
Operating Margin
-190.0%
Net Margin
-221.3%
YoY Growth
43.0%
EPS
$-1.30
REGENXBIO Inc. Q4 FY2025 Financial Summary
REGENXBIO Inc. reported revenue of $30.3M (up 43.0% YoY) for Q4 FY2025, with a net profit of $-67.1M (down 31.2% YoY) (-221.3% margin).
Key Financial Metrics
| Total Revenue | $30.3M |
|---|---|
| Net Profit | $-67.1M |
| Gross Margin | N/A |
| Operating Margin | -190.0% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
REGENXBIO Inc. Q4 FY2025 revenue of $30.3M breaks down across 3 segments, led by Novartis Gene Therapies at $24.2M (79.7% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Novartis Gene Therapies | $24.2M | 79.7% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14.2% |
| Nippon Shinyaku Services | $1.4M | 4.6% |
REGENXBIO Inc. Revenue by Segment — Quarterly Trend
REGENXBIO Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Novartis Gene Therapies and Nippon Shinyaku Collaboration And License Agreement) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Novartis Gene Therapies | $24.2M | $23.6M | $18.4M | $17.0M |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | $5.9M | $2.7M | — |
| Nippon Shinyaku Services | $1.4M | — | — | — |
REGENXBIO Inc. Annual Revenue by Year
REGENXBIO Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $170.4M).
REGENXBIO Inc. Quarterly Revenue & Net Profit History
REGENXBIO Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $30.3M | +43.0% | $-67.1M | -221.3% |
| Q3 FY2025 | $29.7M | +22.9% | $-61.9M | -208.3% |
| Q2 FY2025 | $21.4M | -4.2% | $-70.9M | -331.8% |
| Q1 FY2025 | $89.0M | +469.8% | $6.1M | 6.8% |
| Q4 FY2024 | $21.2M | -4.5% | $-51.2M | -241.3% |
| Q3 FY2024 | $24.2M | -16.3% | $-59.6M | -246.3% |
| Q2 FY2024 | $22.3M | +11.6% | $-53.0M | -237.7% |
| Q1 FY2024 | $15.6M | -18.4% | $-63.3M | -405.4% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $15.6M | $22.3M | $24.2M | $21.2M | $89.0M | $21.4M | $29.7M | $30.3M |
| YoY Growth | -18.4% | 11.6% | -16.3% | -4.5% | 469.8% | -4.2% | 22.9% | 43.0% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $629.2M | $569.4M | $519.1M | $466.0M | $490.9M | $581.0M | $525.2M | $453.0M |
| Liabilities | $238.5M | $221.1M | $217.7M | $206.3M | $216.7M | $367.3M | $363.8M | $350.3M |
| Equity | $390.7M | $348.3M | $301.4M | $259.7M | $274.2M | $213.7M | $161.5M | $102.7M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-55.5M | $-45.5M | $-40.5M | $-31.6M | $33.6M | $-49.3M | $-56.0M | $-52.3M |